---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-23-000067"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:27:21.591545+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Salarius Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Nasdaq notified Salarius on Sept 5, 2023 that average closing bid price fell below $1.00 over prior 30 consecutive trading days.
- Company has 180 calendar days (until March 4, 2024) to regain compliance by having bid price >= $1.00 for 10 consecutive business days.
- If not compliant by March 4, 2024, Salarius may qualify for additional 180-day period if it meets other Nasdaq listing standards.
- Company intends to monitor closing bid price and evaluate options to regain compliance; no immediate effect on listing or trading.

## SEC filing metadata
- accession: 0001615219-23-000067
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000067/0001615219-23-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000067/flks-20230905.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-23-000067
- JSON: https://secwatch.observer/filing/0001615219-23-000067.json
- Plain text: https://secwatch.observer/filing/0001615219-23-000067.txt

## Key facts
- Listing & Compliance Notices
  Decoy Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: September 5, 2023, Salarius Pharmaceuticals, Inc. (the “Company”) was notified (the “Notice”) by Nasdaq Stock Market, LLC (“Nasdaq”) that on September 1, 2023, the average closing price of the Company’s common stock (the “Common Stock”) over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing or trading of the Company’s common stock. In accordance with Nasdaq Listing Rule 581
  evidence_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000067/0001615219-23-000067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.